Johnson & Johnson is already a $100 billion company, and its CEO just told investors he wants to push double-digit growth by the end of the decade.
That kind of math is rare at this scale, and J&J is backing it with a $55 billion bet on U.S. manufacturing across medicines, medical devices, and R&D.
J&J is shifting production of its medicines and medical tech onto American soil, with the latest big check - over $1 billion - going to its vision-care operations in Jacksonville, Florida, which make Acuvue contact lenses and other eye-care products.
Jacksonville is the newest site announced under the broader $55 billion plan, joining previously announced biologics facilities in Wilson and Holly Springs, North Carolina, with additional plants expected across multiple states.
The commitment runs through early 2029 and covers new factories, R&D sites, and tech upgrades to J&J's existing U.S. footprint.
CEO Joaquin Duato told Fox Business the company had wanted to make this shift for years, but the tax code finally made the math work.
"We're playing with a hand tied to our back compared to companies that were domiciled outside of the U.S.," Duato said, crediting the Trump administration's tax policy for making domestic production competitive again.
The shift also gets ahead of looming pharmaceutical tariffs, which the administration has signaled could hit companies that make drugs abroad and ship them into the U.S.
That puts J&J alongside Eli Lilly, Novartis, and Pfizer, all of which have announced multibillion-dollar U.S. manufacturing investments over the past year as tariff pressure and tax incentives push pharma supply chains back home.
The wave of investment marks a sharp shift from the offshoring trend that defined pharma manufacturing through the 2000s and 2010s.
We break down what corporate moves like this actually mean for Market Briefs readers in five minutes a day, plus a free investing masterclass when you join.
The factories aren't just for existing products - they're for a new generation of drugs and devices J&J needs production capacity to launch.
The headliner is Icotyde, a once-daily pill for plaque psoriasis that aims to do what injectable biologics do without the needle.
Approved by the FDA in March 2026, it competes with blockbuster injectables like AbbVie's Skyrizi and J&J's own Tremfya, opening a market worth billions in annual sales.
On the medical-device side, J&J is pushing for approval of its first robotic surgery system, Ottava, which it submitted to the FDA in January 2026 for de novo classification and which would put it in direct competition with Intuitive Surgical's da Vinci platform.
The launches arrive as J&J works to replace revenue from older drugs losing patent protection, making the new pipeline central to the growth story.
Both products fit Duato's framing of J&J as a "stable of blockbusters," with 28 product platforms each generating over $1 billion in annual sales, and the new factories are being built to manufacture the next wave.
Duato says J&J has "line of sight to double-digit growth" by the end of the decade, an ambitious target for a company already projecting more than $100 billion in 2026 sales.
Backing the call is the $55 billion buildout, but the growth story hinges on whether Icotyde gains commercial traction and whether the robotic surgery system clears regulators and gains traction once launched.
FDA decisions and Jacksonville progress reports through 2026 will be the next milestones to watch.
If you want this kind of read on the market every morning, join 350,000+ investors reading Market Briefs - you also get a 45-minute investing course as a bonus.
